Skip To Main Content

Search

For optimal search results, please limit to 2 product keywords

If you are searching for information related to a product:

  • For optimal results, please enter at least 2 search terms in addition to product name
  • Example: [product name] [search term] [search term]
  • Example: Product + clinical trials
  • For an exact match, please include search terms in double quotations. For example: "Elevatum"

    Please enter search terms.

    Prasinezumab

    Other names: RG7935; RO7046015

    Modality: Humanised IgG1 monoclonal antibody that selectively binds aggregated α-synuclein

    Disease State: Early stage Parkinson’s disease (PD)

    Summary

    Prasinezumab is an investigational humanised IgG1 monoclonal antibody that selectively binds aggregated α-synuclein.

    Clinical Trials

    Prasinezumab
    NCT ID Study Phase Enrollment Status Study Title
    NCT07174310 Phase III Recruiting A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease View details
    NCT04777331 Phase II Active, not recruiting A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease View details
    NCT03100149 Phase II Active, not recruiting A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease View details

    Proposed Mechanism of Action

    Prasinezumab’s proposed mode of action for the treatment of Parkinson’s disease: Prasinezumab is a humanized IgG1 monoclonal antibody that binds extracellular alpha-synuclein (α-syn) aggregates, which may prevent their toxic spread between neurons and reduce neuronal toxicity.1-6

    1. Brundin P, Dave K, Kordower J. Therapeutic approaches to target alpha-synuclein pathology. Exp Neurol. 2017;298(Pt B):225–235. doi:10.1016/​j.expneurol.2017.10.003
    2. Calabresi P, Mechelli A, Natale G, et al. Alpha-synuclein in Parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 2023;14(3):176. doi:10.1038/​s41419-023-05672-9
    3. Schenk D, Koller M, Ness DK, et al. First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers. Mov Disord. 2017;32(2):211-218. doi:10.1002/​mds.26878
    4. Bellingacci L, Sciaccaluga M, Megaro A, et al. Oligomeric alpha-synuclein causes early synaptic dysfunction of the corticostriatal pathway associated with non-motor symptoms. NPJ Parkinsons Dis. 2025;11(1):220. doi:10.1038/​s41531-025-01075-z
    5. Xiao B, Tan E. Prasinezumab slows motor progression in Parkinson’s disease: beyond the clinical data. NPJ Parkinsons Dis. 2025;11(1):31. doi:10.1038/​s41531-025-00886-4
    6. Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease. News release. Roche; June 15, 2025. Accessed January 13, 2026.
    7. Angot E, Steiner JA, Hansen C, et al. Are synucleinopathies prion-like disorders? Lancet Neurol. 2010;9(11):1128–1138. doi:10.1016/​S1474-4422(10)70213-1
    8. Vekrellis K, Stefanis L. Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies. Expert Opin Ther Targets. 2012;16(4):421–432. doi:10.1517/​14728222.2012.674111 https://www.roche.com/​media/​releases/​med-cor-2025-06-16.

    Looking for more information?

    Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.

    Connect with an MSL
    Submit a Request

    Call the Trial Information Support Team: 1-888-662-6728 Hours: Monday-Friday, 5am-5pm PT

    TOP

    • α-syn/α-synuclein
      Alpha-synuclein

    • IgG1
      Immunoglobulin G1

    • PD
      Parkinson’s disease

    +